---
layout: post
title: "贵州百灵：获得药物临床试验补充申请批准通知书"
date: 2021-12-27 17:54:21 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002424" data-code="002424|0|2" data-code2="002424|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002424&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002424_0" data-code="K 002424|0|2" data-code2="K 002424|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>贵州百灵(002424)12月27日晚间公告，公司全资子公司正鑫药业药品双羊喉痹通颗粒获得药物临床试验补充申请批准通知书。本次拟变更适用人群范围，用于急性咽炎、急性扁桃体炎(外感风热证)所致的咽喉肿痛的儿童患者。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202112272227385731>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)